Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple-Negative Breast Cancer

Next Previous
Trial Profile

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple-Negative Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Sponsors Genentech

Most Recent Events

  • 28 Apr 2020 Results (n=1427) assessing the prognostic value of the T effector RNA gene signature (Teff) in four studies (BO20289, NO17629, GO25632 and OAM4861G), presented at the 111th Annual Meeting of the American Association for Cancer Research - I.
  • 04 May 2016 Status changed from active, no longer recruiting to completed.
  • 22 Jul 2015 Primary endpoint (Progression-free survival duration) has not been met, according to a results published in the Annals of Oncology journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top